Alnylam pharmaceuticals, inc. (ALNY)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Dec'10Sep'10Jun'10Mar'10
Cash flows from operating activities:
Net loss

-182,221

-276,185

-208,535

-219,481

-181,915

-211,441

-245,282

-163,560

-141,214

-142,227

-122,937

-118,420

-107,290

-112,934

-104,071

-90,129

-102,974

-90,721

-76,792

-71,783

-50,777

-21,389

-43,989

-44,074

-250,943

-32,357

-29,686

-18,169

-9,013

-62,188

-19,502

-12,956

-11,368

-14,303

-13,237

-13,824

-16,285

-6,930

-9,630

-14,632

-12,323

Non-cash adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

7,613

5,442

-10,222

18,117

3,838

9,426

405

2,239

3,178

2,245

3,587

3,066

3,000

3,018

3,500

4,011

4,601

5,069

5,270

5,021

3,690

3,341

3,117

2,868

2,600

2,627

2,764

2,711

2,127

2,024

2,285

2,605

2,121

1,237

1,262

1,287

1,339

1,291

1,266

1,223

1,161

Amortization and interest accretion related to operating leases

9,393

-

-

-

10,255

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

10,875

11

-13

-131

Stock-based compensation

34,578

66,197

46,009

30,603

32,032

27,973

87,954

22,241

19,584

27,117

25,955

24,030

15,717

20,651

15,581

15,816

23,480

15,520

11,848

10,179

8,236

13,438

6,352

7,680

5,591

5,406

8,845

3,377

3,075

2,722

3,386

3,096

3,156

4,082

4,258

4,214

4,122

4,212

4,511

5,068

5,327

Charge for 401(k) company stock match

-

-

-

-

-

-

1,286

1,384

942

-

661

523

551

305

421

450

331

209

254

274

247

179

845

-175

-157

800

-104

-367

120

-674

98

116

96

95

119

412

-138

897

-131

-404

133

Unrealized gain on marketable equity securities

24,111

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Equity in loss of joint venture (Regulus Therapeutics Inc.)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-881

-1,613

-1,139

-889

-954

-467

-1,012

-1,072

-916

-1,226

-3,919

-1,578

Realized loss on sale of marketable equity securities

-

-

-

-

-

-

-

-

-

-

0

-345

-1,549

-

706

954

5,156

-

-

-

-

-

-

-

-

-

-

-

-

76

0

4

175

-

-

-

-

-

-

-

-

Other

660

1,224

-5,201

1,861

-1,075

-

-

-

-

3,771

0

0

608

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Benefit from intraperiod tax allocation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-431

-22,091

67

-315

-17,870

3,021

-2,270

-2,884

-562

-

-

-

-

-

-

-

-

-

-

-

-

In-process research and development

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

224,656

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivable, net

32,882

-5,479

17,783

-3,107

15,041

15,398

401

-47,807

16,766

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from landlord lease incentive for tenant improvements

0

-1,106

-10,364

-6,314

-12,386

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-12

0

0

-192

-

-

-

-

-

-

-

-

-

-

-

-

Inventory

11,952

4,316

13,055

7,906

7,134

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Billed and unbilled collaboration receivables

-

-

-

-

-

-

-

-

-

-

-

-4,052

-3,877

-

5,632

700

516

168

-1,273

-704

-29,830

39,553

295

-75

-4,084

3,639

149

-98

454

-1,814

-2,467

2,193

724

-559

719

158

-2,300

-1,431

-1,477

1,853

-1,539

Income taxes receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-10,669

-

-

-

-

Prepaid expenses and other assets

19,958

8,380

18,525

-13,851

8,988

942

12,864

-6,279

27,540

18,659

1,854

3,906

-3,708

2,463

-2,780

3,583

2,010

-606

2,336

1,911

3,179

-960

429

1,861

4,499

-866

572

706

944

-3,139

-1,254

-319

2,932

-751

-168

158

-1,970

457

411

912

958

Accounts payable, accrued expenses and other liabilities

-14,215

-

-

-

-24,332

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable

-

-

-

-

-

-

9,085

-693

-9,042

-

-8,945

2,741

-11,067

11,560

2,128

-3,937

347

2,561

310

-1,945

750

9,666

-947

1,500

-1,379

3,168

-1,806

1,429

-959

-1,029

-426

1,180

-1,461

314

-2,463

2,149

-3,512

2,751

-3,837

3,410

-5,501

Income taxes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

30

1

-1

-5,546

Accrued expenses and other liabilities

-

-

-

-

-

-

17,981

19,028

-11,767

-

9,394

7,451

-10,855

3,924

5,032

6,022

-4,305

10,818

2,434

1,523

-8,432

1,831

5,056

-1,538

3,773

-2,324

6,914

-1,253

-1,790

-6,269

91

2,335

252

716

831

-870

1,780

98

3,123

-1,362

-1,208

Deferred revenue

-4,030

-7,333

411

400,007

-834

-1,113

-8,616

-29,848

26,961

7,892

-4,985

-931

-128

5,951

3,286

2,799

2,579

2,668

3,374

2,051

-6,189

16,556

-9,252

-7,245

-7,845

753

-5,859

-8,332

7,237

16,106

12,732

-17,331

-20,069

-19,684

-20,306

-20,367

-9,898

-19,828

-22,122

-19,083

328

Operating lease liability

9,036

-

-

-

7,702

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-246,161

-195,980

-182,632

288,695

-188,510

-150,457

-153,808

-102,687

-155,664

-103,044

-98,363

-81,049

-100,330

-78,337

-75,536

-70,205

-83,623

-53,064

-54,365

-55,456

-26,255

-36,635

-40,706

-46,625

-41,675

-22,369

-21,715

-23,602

-971

-68,912

5,212

-21,694

-30,215

-25,159

-29,025

-26,579

-6,305

-20,388

-24,038

-24,314

-15,601

Cash flows from investing activities:
Purchases of property, plant and equipment

19,617

38,805

36,058

21,244

44,049

37,513

45,409

22,708

21,257

20,728

25,678

21,651

36,152

19,879

20,298

21,621

2,759

3,099

6,477

1,264

2,110

3,526

3,195

1,852

388

878

950

379

1,799

686

5,729

1,670

263

524

265

474

28

1,138

1,067

1,430

1,097

Purchases of restricted investments and increase in restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,183

0

0

288

-

-

-

-

-

-

-

-

0

0

0

162

-

-

-

-

-

-

-

-

Purchases of marketable debt securities

396,409

630,293

611,069

577,567

256,996

111,661

349,598

284,354

358,433

391,431

274,842

150,381

86,803

143,647

257,671

193,431

164,561

135,802

80,371

310,053

507,617

125,102

84,163

280,912

487,598

29,108

60,769

87,351

187,077

81,457

38,568

38,894

118,210

75,294

54,062

121,969

41,790

102,980

105,417

100,965

81,111

Sales and maturities of marketable securities

539,614

455,248

607,050

309,409

403,697

398,138

491,181

384,508

244,876

131,571

163,342

104,361

198,031

263,917

246,564

311,660

294,317

218,357

135,518

204,381

168,687

150,063

125,264

54,389

133,206

86,034

59,215

34,521

58,036

125,656

62,150

48,165

53,042

96,602

90,578

125,080

64,105

151,697

111,168

75,432

74,746

Purchases of restricted investments

9,900

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deposit for manufacturing facility

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

9,057

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment for asset acquisition

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

25,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by investing activities

113,688

-220,850

-10,077

-289,402

102,652

248,964

96,174

62,621

-134,814

-160,588

-137,178

-67,671

75,076

100,391

-31,405

-44,335

117,940

78,273

48,670

-106,936

-341,328

21,435

37,906

-228,375

-379,780

56,048

-2,504

-53,209

-130,840

43,513

17,853

7,601

-65,593

20,784

36,251

2,637

22,287

47,579

4,684

-26,963

-7,462

Cash flows from financing activities:
Proceeds from exercise of stock options and other types of equity, net

53,869

40,342

9,217

12,694

9,031

5,378

12,357

5,641

42,094

42,285

28,956

9,875

2,769

3,437

4,424

4,442

1,824

6,543

3,831

7,197

13,566

7,685

5,056

5,138

11,541

8,924

11,199

3,982

4,638

997

4,499

628

847

267

0

462

9

527

53

1,548

542

Offering proceeds, net of costs

0

0

0

0

381,900

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

496,400

-

-

-

-

0

0

0

173,572

0

0

0

86,800

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

14,301

0

0

0

89,018

0

0

0

723,037

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payments for repurchase of common stock for employee tax withholding

-

-

-

-

-

-

-

60

572

-

41

94

53

355

78

104

59

-

-

-

-

27

262

0

15,703

-

-

-

-

31

0

0

328

-

-

-

-

-

-

-

-

Net cash provided by financing activities

53,869

40,342

-20,699

412,610

390,931

5,378

12,989

5,581

41,522

706,948

28,915

386,312

2,716

3,082

4,346

154,338

16,066

6,468

3,651

7,074

598,984

7,658

4,794

5,138

718,875

7,650

11,084

3,982

178,210

966

4,499

628

87,319

267

0

462

9

527

53

2,541

542

Effect of exchange rate changes on cash, cash equivalents and restricted cash

-631

366

-446

-3

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net (decrease) increase in cash, cash equivalents and restricted cash

-79,235

-376,122

-213,854

411,900

305,073

103,885

-44,645

-34,485

-248,956

443,316

-206,626

237,592

-22,538

25,136

-102,595

39,798

50,383

31,677

-2,044

-155,318

231,401

-7,542

1,994

-269,862

297,420

41,329

-13,135

-72,829

46,399

-24,433

27,564

-13,465

-8,489

-4,108

7,226

-23,480

15,991

27,718

-19,301

-48,765

-22,521

Supplemental disclosure of noncash investing and financing activities:
Capital expenditures included in accounts payable and accrued expenses

6,619

-4,047

-6,970

12,860

13,033

13,535

-3,549

12,851

10,437

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Lease liabilities arising from obtaining right-of-use assets

2,939

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-